Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leah Isakov

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
American Journal of Therapeutics|January 15, 2016
Statistical Primer on Biosimilar Clinical DevelopmentLeah Isakov, Bo Jin, Ira Allen Jacobs
Pharmacoeconomics|June 30, 2017
Assessing the Value of Biosimilars: A Review of the Role of Budget Impact AnalysisSteven Simoens, Ira Jacobs, Robert Popovian, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 26, 2016
Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published EvidenceIra Jacobs, Danielle Petersel, Leah Isakov, et al.
Journal of Clinical Microbiology|June 5, 2020
Comparability of Titers of Antibodies against Seasonal Influenza Virus Strains as Determined by Hemagglutination Inhibition and Microneutralization AssaysMarten Heeringa, Brett Leav, Igor Smolenov, et al.
Vaccine|April 26, 2025
Corrigendum to 'A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older' Vaccine 51 (2025) 126791Brandon J Essink, Wim Vermeulen, Coralie Andrade, et al.
Vaccine|February 13, 2025
A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and olderBrandon J Essink, Wim Vermeulen, Coralie Andrade, et al.
Plos One|December 28, 2020
A cost/benefit analysis of clinical trial designs for COVID-19 vaccine candidatesDonald A Berry, Scott Berry, Peter Hale, et al.
Vaccines|October 28, 2023
Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50-64 Years of AgeAiri Poder, Janine Oberije, Jay Meyer, et al.
The Lancet. Respiratory Medicine|April 11, 2018
Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trialTimo Vesikari, Judith Kirstein, Grace Devota Go, et al.
Lancet (London, England)|July 8, 2008
An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trialChristopher Wood, Pramod Srivastava, Ronald Bukowski, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
American Journal of Therapeutics|January 15, 2016
Statistical Primer on Biosimilar Clinical DevelopmentLeah Isakov, Bo Jin, Ira Allen Jacobs
Pharmacoeconomics|June 30, 2017
Assessing the Value of Biosimilars: A Review of the Role of Budget Impact AnalysisSteven Simoens, Ira Jacobs, Robert Popovian, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 26, 2016
Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published EvidenceIra Jacobs, Danielle Petersel, Leah Isakov, et al.
Journal of Clinical Microbiology|June 5, 2020
Comparability of Titers of Antibodies against Seasonal Influenza Virus Strains as Determined by Hemagglutination Inhibition and Microneutralization AssaysMarten Heeringa, Brett Leav, Igor Smolenov, et al.
Vaccine|April 26, 2025
Corrigendum to 'A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older' Vaccine 51 (2025) 126791Brandon J Essink, Wim Vermeulen, Coralie Andrade, et al.
Vaccine|February 13, 2025
A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and olderBrandon J Essink, Wim Vermeulen, Coralie Andrade, et al.
Plos One|December 28, 2020
A cost/benefit analysis of clinical trial designs for COVID-19 vaccine candidatesDonald A Berry, Scott Berry, Peter Hale, et al.
Vaccines|October 28, 2023
Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50-64 Years of AgeAiri Poder, Janine Oberije, Jay Meyer, et al.
The Lancet. Respiratory Medicine|April 11, 2018
Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trialTimo Vesikari, Judith Kirstein, Grace Devota Go, et al.
Lancet (London, England)|July 8, 2008
An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trialChristopher Wood, Pramod Srivastava, Ronald Bukowski, et al.
Pageof 1